トラベルワクチンの世界市場レポート 2025年

トラベルワクチンの市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.9％で74億9,000万米ドルに成長します。予測期間の成長は、出張頻度の増加、新たな感染症の脅威、政府の規制と入国要件、エキゾチックな旅行先への需要の高まり、政府と製薬会社の協力関係などに起因すると考えられます。予測期間の主な動向としては、オーダーメイドのワクチン接種戦略、非蔓延地域への市場拡大、デジタルヘルス技術の採用、規制支援、承認の合理化、革新的開発などが挙げられます。

予想される旅行・観光客の急増は、今後の旅行用ワクチン市場の拡大を牽引する構えです。旅行と観光は、列車、船、飛行機、その他の交通手段を含む、さまざまな離れた地理的地域を横断する人と車両の移動を包含します。トラベルワクチンは、海外旅行中の観光客や旅行者の安全と健康を確保する上で重要な役割を果たしています。国連世界観光機関（UNWTO）は、2023年1月時点で、2022年に海外旅行をした観光客数は9億人を超え、前年比で2倍、パンデミック前の水準から63%という大幅な増加を記録したと報告しています。この旅行と観光の急増は、旅行用ワクチン市場の成長を牽引する重要な要因となっています。

旅行用ワクチン市場の成長を牽引しているのは、ヘルスケア支出の増加です。ヘルスケア支出とは、特定の地域、国、組織内のヘルスケア部門に割り当てられる総財源を指します。この支出には、予防措置としてのトラベルワクチンへの投資が含まれ、渡航関連疾患の治療に伴う経済的負担の軽減に役立っています。トラベルワクチンは、海外旅行中の感染症リスクを最小限に抑えることで、帰国後の治療、入院、感染の可能性に関するコストを回避し、公衆衛生において重要な役割を果たしています。例えば、2024年9月、米国を拠点とするABAセラピー・サービスを提供するクロス・リバー・セラピー社が発表した統計によると、米国の製薬業界の売上高は5,500億米ドルでした。2021年、アメリカ人は医薬品に5,769億米ドルを費やし、2025年には6,050億米ドルから6,350億米ドルに増加すると予測されています。したがって、ヘルスケア支出の増加は、旅行用ワクチン市場の今後の成長を推進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のトラベルワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のトラベルワクチン市場：成長率分析
• 世界のトラベルワクチン市場の実績：規模と成長, 2019-2024
• 世界のトラベルワクチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界のトラベルワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のトラベルワクチン市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• A型肝炎
• ジフテリア、百日咳、破傷風（DPT）
• 黄熱病
• 腸チフス
• B型肝炎
• 麻疹とおたふく風邪
• 狂犬病
• 髄膜炎菌
• その他の疾患
• 世界のトラベルワクチン市場：構成別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単核ワクチン
• 混合ワクチン
• 世界のトラベルワクチン市場：予約チャンネル、実績と予測, 2019-2024, 2024-2029F, 2034F
• オンライン予約
• 対面予約
• 世界のトラベルワクチン市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 国内旅行
• 出国旅行
• 世界のトラベルワクチン市場、タイプ別サブセグメンテーション：A型肝炎、実績と予測, 2019-2024, 2024-2029F, 2034F
• 不活化A型肝炎ワクチン
• 混合ワクチン
• 世界のトラベルワクチン市場、タイプ別サブセグメンテーション：ジフテリア、百日咳、破傷風（DPT）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 不活化A型肝炎ワクチン
• 混合ワクチン
• 世界のトラベルワクチン市場、疾患別サブセグメンテーション：黄熱病、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生弱毒化黄熱ワクチン
• 追加接種ワクチン
• 世界のトラベルワクチン市場、タイプ別サブセグメンテーション：腸チフス、実績と予測, 2019-2024, 2024-2029F, 2034F
• 不活化腸チフスワクチン
• 生弱毒化腸チフスワクチン
• 世界のトラベルワクチン市場、タイプ別サブセグメンテーション：B型肝炎、実績と予測, 2019-2024, 2024-2029F, 2034F
• 組み換えB型肝炎ワクチン
• 混合ワクチン
• 世界のトラベルワクチン市場、タイプ別サブセグメンテーション：麻疹とおたふく風邪、実績と予測, 2019-2024, 2024-2029F, 2034F
• 麻疹・風疹・おたふく風邪（MMR）ワクチン
• 麻疹・風疹（MR）ワクチン
• 世界のトラベルワクチン市場、タイプ別サブセグメンテーション：狂犬病、実績と予測, 2019-2024, 2024-2029F, 2034F
• 狂犬病暴露前予防（PrEP）
• 狂犬病暴露後予防（PEP）
• 世界のトラベルワクチン市場、タイプ別サブセグメンテーション：髄膜炎菌、実績と予測, 2019-2024, 2024-2029F, 2034F
• 髄膜炎菌結合ワクチン
• 髄膜炎菌Bワクチン
• 世界のトラベルワクチン市場、タイプ別サブセグメンテーション：その他の疾患、実績と予測, 2019-2024, 2024-2029F, 2034F
• 日本脳炎
• コレラ
• インフルエンザ
• その他の新興トラベルワクチン

第7章 地域別・国別分析

• 世界のトラベルワクチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のトラベルワクチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• トラベルワクチン市場：競合情勢
• トラベルワクチン市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Biological E. Limited
• Takeda Pharmaceutical Company Limited
• Novavax Inc.
• Emergent BioSolutions UK
• Serum Institute of India Pvt. Ltd.
• Dynavax Technologies
• Bavarian Nordic A/S
• Valneva SE
• Panacea Biotec
• Vabiotech
• Inovio Pharmaceuticals
• Bharat Biotech International Limited
• Altimmune Inc.
• Bio Farma
• Vaxart Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• トラベルワクチン市場2029：新たな機会を提供する国
• トラベルワクチン市場2029：新たな機会を提供するセグメント
• トラベルワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Travel vaccines are immunizations designed to protect against diseases prevalent in either the country of origin or the destination. Their purpose is to ensure the well-being of travelers and prevent the transmission of diseases within and between nations.

The primary travel vaccines targeting various diseases include hepatitis A, diphtheria, pertussis, and tetanus (DPT), yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal, and others. Hepatitis A is caused by the hepatitis A virus (HAV), leading to liver inflammation. These vaccines are available as mono vaccines or combination vaccines and can be booked through online and in-person channels for domestic travel, as well as through outbound travel applications.

The travel vaccine market research report is one of a series of new reports from The Business Research Company that provides travel vaccine market statistics, including the travel vaccine industry global market size, regional shares, competitors with a travel vaccine market share, detailed travel vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the travel vaccine industry. This travel vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The travel vaccines market size has grown strongly in recent years. It will grow from $4.73 billion in 2024 to $5.14 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to increased international travel, government initiatives for travel health, globalization of diseases, growing awareness among travelers, and expansion of the travel and tourism industry

The travel vaccines market size is expected to see strong growth in the next few years. It will grow to $7.49 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to the increasing frequency of business travel, emerging infectious disease threats, government regulations and entry requirements, rising demand for exotic destinations, and collaboration between governments and pharmaceutical companies. Major trends in the forecast period include tailored vaccination strategies, expansion of the market to non-endemic regions, adoption of digital health technologies, regulatory support, and streamlined approvals, innovative developments.

The anticipated surge in travel and tourism is poised to drive the expansion of the travel vaccine market in the future. Travel and tourism encompass the movement of people and vehicles across various distant geographic areas, including trains, boats, airplanes, and other modes of transportation. Travel vaccines play a crucial role in ensuring the safety and health of tourists and travelers during their journeys abroad. As of January 2023, the United Nations World Tourism Organization (UNWTO) reported that over 900 million tourists ventured abroad in 2022, marking a twofold increase from the previous year and a substantial 63% rise from pre-pandemic levels. This surge in travel and tourism is a significant factor propelling the growth of the travel vaccine market.

The growth of the travel vaccine market is being driven by the increase in healthcare spending. Healthcare spending refers to the total financial resources allocated to the healthcare sector within a specific region, country, or organization. This spending includes investments in travel vaccines as a preventive measure, which helps reduce the economic burden associated with treating travel-related diseases. Travel vaccines play a vital role in public health by minimizing the risk of infectious diseases during international travel, thereby avoiding costs related to medical treatment, hospitalization, and potential outbreaks upon return. For example, in September 2024, statistics published by Cross River Therapy, a US-based provider of ABA therapy services, indicated that the U.S. pharmaceutical industry generated $550 billion in revenue. In 2021, Americans spent $576.9 billion on medicine, with projected spending expected to rise to between $605 and $635 billion by 2025. Therefore, the increase in healthcare spending is propelling the growth of the travel vaccine market moving forward.

Product innovation stands out as a prominent trend gaining traction in the travel vaccine market, with major companies actively pursuing the development of innovative vaccines to strengthen their market positions. For example, in August 2022, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, received approval for QDENGA (Dengue Tetravalent Vaccine) (TAK-003) from the Indonesia National Agency for Drug and Food Control. QDENGA, designed for the prevention of dengue sickness in individuals aged six to 45, demonstrated sustained overall protection against dengue sickness and hospitalization three years after immunization, regardless of prior exposure to the disease.

Major companies operating in the travel vaccine market are developing innovative vaccines to provide active immunization to prevent Hepatitis A common concern for travelers. A travel vaccine is a vaccine specifically designed to protect individuals from infectious diseases that are prevalent in certain regions or countries, often recommended for travelers visiting those areas. For instance, in January 2024, Indian Immunologicals Ltd. (IIL), an India-based biotechnology company, launched Havisure, India's first indigenously developed Hepatitis A vaccine. Havisure is anticipated to be instrumental in providing protection against the Hepatitis A virus, which mainly impacts the liver. This vaccine is effective in preventing the disease and is advised for children as part of routine immunization. Additionally, it is recommended for individuals at risk of exposure or those traveling to areas with high rates of hepatitis A.

In May 2023, Bavarian Nordic, a US-based biopharmaceutical company, acquired Emergent BioSolutions' travel vaccine portfolio for an undisclosed amount. This strategic acquisition includes two commercially available vaccines-Vivotif for preventing typhoid fever and Vaxchora for cholera prevention-as well as a Phase 3 vaccine candidate targeting the prevention of the Chikungunya virus. The deal also encompasses R&D facilities in the US, a Swiss biologics production facility, and EU and US commercial operations with a specialized salesforce. Emergent BioSolutions, a US-based biotechnology firm, specialized in manufacturing devices, vaccines, and therapeutics, with its travel vaccine division being part of the acquisition.

Major companies operating in the travel vaccines market include Pfizer Inc., Johnson and Johnson, Merck & Co. Inc., Sanofi SA, GlaxoSmithKline plc, Biological E. Limited, Takeda Pharmaceutical Company Limited, Novavax Inc., Emergent BioSolutions UK, Serum Institute of India Pvt. Ltd., Dynavax Technologies, Bavarian Nordic A/S, Valneva SE, Panacea Biotec, Vabiotech, Inovio Pharmaceuticals, Bharat Biotech International Limited, Altimmune Inc., Bio Farma, Vaxart Inc.

North America was the largest region in the travel vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the travel vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the travel vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The travel vaccine market consists of sales of vaccines for diseases such as Japanese encephalitis, tick-borne encephalitis, and tuberculosis (TB). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Travel Vaccines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on travel vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for travel vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The travel vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease: Hepatitis A; Diphtheria, Pertussis, And Tetanus (DPT); Yellow Fever; Typhoid; Hepatitis B; Measles And Mumps; Rabies; Meningococcal; Other Diseases;
• 2) By Composition: Mono Vaccines; Combination Vaccines
• 3) By Booking Channel: Online Booking; In-Person Booking
• 4) By Application: Domestic Travel; Outbound Travel
• Subsegments:
• 1) By Hepatitis A: Inactivated Hepatitis A Vaccine; Combination Vaccines
• 2) By Diphtheria, Pertussis, And Tetanus (DPT): DTP Vaccine (Diphtheria, Tetanus, Pertussis); DTaP Vaccine (Diphtheria, Tetanus, And Acellular Pertussis)
• 3) By Yellow Fever: Live Attenuated Yellow Fever Vaccine; Booster Dosage Vaccines
• 4) By Typhoid: Inactivated Typhoid Vaccine; Live Attenuated Typhoid Vaccine
• 5) By Hepatitis B: Recombinant Hepatitis B Vaccine; Combination Vaccines
• 6) By Measles And Mumps: Measles, Mumps, And Rubella (MMR) Vaccine; Measles And Rubella (MR) Vaccine
• 7) By Rabies: Rabies Pre-exposure Prophylaxis (PrEP); Rabies Post-exposure Prophylaxis (PEP)
• 8) By Meningococcal: Meningococcal Conjugate Vaccine; Meningococcal B Vaccine
• 9) By Other Diseases: Japanese Encephalitis; Cholera; Influenza; Other Emerging Travel Vaccines
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson; Merck & Co. Inc.; Sanofi SA; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Travel Vaccines Market Characteristics

3. Travel Vaccines Market Trends And Strategies

4. Travel Vaccines Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Travel Vaccines Growth Analysis And Strategic Analysis Framework

• 5.1. Global Travel Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Travel Vaccines Market Growth Rate Analysis
• 5.4. Global Travel Vaccines Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Travel Vaccines Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Travel Vaccines Total Addressable Market (TAM)

6. Travel Vaccines Market Segmentation

• 6.1. Global Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis A
• Diphtheria, Pertussis, And Tetanus (DPT)
• Yellow Fever
• Typhoid
• Hepatitis B
• Measles And Mumps
• Rabies
• Meningococcal
• Other Diseases
• 6.2. Global Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mono Vaccines
• Combination Vaccines
• 6.3. Global Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Booking
• In-Person Booking
• 6.4. Global Travel Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Domestic Travel
• Outbound Travel
• 6.5. Global Travel Vaccines Market, Sub-Segmentation Of Hepatitis A, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inactivated Hepatitis A Vaccine
• Combination Vaccines
• 6.6. Global Travel Vaccines Market, Sub-Segmentation Of Diphtheria, Pertussis, And Tetanus (DPT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inactivated Hepatitis A Vaccine
• Combination Vaccines
• 6.7. Global Travel Vaccines Market, Sub-Segmentation Of Yellow Fever, By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Live Attenuated Yellow Fever Vaccine
• Booster Dosage Vaccines
• 6.8. Global Travel Vaccines Market, Sub-Segmentation Of Typhoid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inactivated Typhoid Vaccine
• Live Attenuated Typhoid Vaccine
• 6.9. Global Travel Vaccines Market, Sub-Segmentation Of Hepatitis B, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Hepatitis B Vaccine
• Combination Vaccines
• 6.10. Global Travel Vaccines Market, Sub-Segmentation Of Measles And Mumps, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Measles, Mumps, And Rubella (MMR) Vaccine
• Measles And Rubella (MR) Vaccine
• 6.11. Global Travel Vaccines Market, Sub-Segmentation Of Rabies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rabies Pre-exposure Prophylaxis (PrEP)
• Rabies Post-exposure Prophylaxis (PEP)
• 6.12. Global Travel Vaccines Market, Sub-Segmentation Of Meningococcal, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Meningococcal Conjugate Vaccine
• Meningococcal B Vaccine
• 6.13. Global Travel Vaccines Market, Sub-Segmentation Of Other Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Japanese Encephalitis
• Cholera
• Influenza
• Other Emerging Travel Vaccines

7. Travel Vaccines Market Regional And Country Analysis

• 7.1. Global Travel Vaccines Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Travel Vaccines Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Travel Vaccines Market

• 8.1. Asia-Pacific Travel Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Travel Vaccines Market

• 9.1. China Travel Vaccines Market Overview
• 9.2. China Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Travel Vaccines Market

• 10.1. India Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Travel Vaccines Market

• 11.1. Japan Travel Vaccines Market Overview
• 11.2. Japan Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Travel Vaccines Market

• 12.1. Australia Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Travel Vaccines Market

• 13.1. Indonesia Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Travel Vaccines Market

• 14.1. South Korea Travel Vaccines Market Overview
• 14.2. South Korea Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Travel Vaccines Market

• 15.1. Western Europe Travel Vaccines Market Overview
• 15.2. Western Europe Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Travel Vaccines Market

• 16.1. UK Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Travel Vaccines Market

• 17.1. Germany Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Travel Vaccines Market

• 18.1. France Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Travel Vaccines Market

• 19.1. Italy Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Travel Vaccines Market

• 20.1. Spain Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Travel Vaccines Market

• 21.1. Eastern Europe Travel Vaccines Market Overview
• 21.2. Eastern Europe Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Travel Vaccines Market

• 22.1. Russia Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Travel Vaccines Market

• 23.1. North America Travel Vaccines Market Overview
• 23.2. North America Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Travel Vaccines Market

• 24.1. USA Travel Vaccines Market Overview
• 24.2. USA Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Travel Vaccines Market

• 25.1. Canada Travel Vaccines Market Overview
• 25.2. Canada Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Travel Vaccines Market

• 26.1. South America Travel Vaccines Market Overview
• 26.2. South America Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Travel Vaccines Market

• 27.1. Brazil Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Travel Vaccines Market

• 28.1. Middle East Travel Vaccines Market Overview
• 28.2. Middle East Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Travel Vaccines Market

• 29.1. Africa Travel Vaccines Market Overview
• 29.2. Africa Travel Vaccines Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Travel Vaccines Market, Segmentation By Composition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Travel Vaccines Market, Segmentation By Booking Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Travel Vaccines Market Competitive Landscape And Company Profiles

• 30.1. Travel Vaccines Market Competitive Landscape
• 30.2. Travel Vaccines Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Travel Vaccines Market Other Major And Innovative Companies

• 31.1. Biological E. Limited
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Novavax Inc.
• 31.4. Emergent BioSolutions UK
• 31.5. Serum Institute of India Pvt. Ltd.
• 31.6. Dynavax Technologies
• 31.7. Bavarian Nordic A/S
• 31.8. Valneva SE
• 31.9. Panacea Biotec
• 31.10. Vabiotech
• 31.11. Inovio Pharmaceuticals
• 31.12. Bharat Biotech International Limited
• 31.13. Altimmune Inc.
• 31.14. Bio Farma
• 31.15. Vaxart Inc.

32. Global Travel Vaccines Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Travel Vaccines Market

34. Recent Developments In The Travel Vaccines Market

35. Travel Vaccines Market High Potential Countries, Segments and Strategies

• 35.1 Travel Vaccines Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Travel Vaccines Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Travel Vaccines Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer